Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN
Regeneron Pharmaceuticals — J.P. Morgan Healthcare Conference 2013
21 slides from Regeneron Pharmaceuticals's conference presentation, Jan 8, 2013
Slide 1: J.P. Morgan Healthcare Conference January 2013
J.P. Morgan Healthcare Conference January 2013 Exhibit 99.1
Slide 2: Safe Harbor Statement
2 SAFE HARBOR STATEMENT Except for historical information, the matters contained in this presentation may constitute forward-looking statements that involve risks and uncertainties, including risks and uncertainties related to product development and clinical trials, unforeseen safety issues resulti
Slide 3: Regeneron Transformed
Slide 4: Regeneron Transformed
4 REGENERON TRANSFORMED One of the top 5 biopharmaceutical launches of all time EYLEA ® LAUNCH HAS EXCEEDED EXPECTATIONS EYLEA US, EU, Japan, Australia, and other countries; ZALTRAP US MULTIPLE REGULATORY APPROVALS GAAP & N on - GAAP FOUR FULL QUARTERS OF PROFITABILITY Year end cash and receivables
Slide 5: Regeneron Looking Forward
5 REGENERON LOOKING FORWARD RESEARCH & DEVELOPMENT Expanding late stage pipeline with REGN727 (PCSK9), Sarilumab (IL6R), & REGN668 (IL4R) Continuing to invest in early stage pipeline and innovative technologies EYLEA Increasing market share, expanding geographies and indications, securing future ZAL
Slide 6: EYLEA U.S. launch exceeding expectations
6 * 4Q12 Sales Estimate EYLEA net product sales of $276 million in 4Q12* $838 million in full year 2012* 2013 EYLEA U.S. net sales guidance: ~50% growth (i.e. ~$1.2B to $1.3B) U.S. LAUNCH EXCEEDING EXPECTATIONS
Slide 7: Expanding Branded Market
7 * 4Q12 Sales Estimate 0 100 200 300 400 500 600 700 3Q11 4Q11 1Q12 2Q12 3Q12 4Q12 EYLEA Lucentis EYLEA & Lucentis Total + 47 % EXPANDING BRANDED MARKET
Slide 8: Expanding Geography
8 3Q11 4Q11 1Q12 2Q12 3Q12 0 100 200 300 400 500 600 700 US: EYLEA US: Lucentis exUS: Lucentis EXPANDING GEOGRAPHY
Slide 9: Broadening Indications
9 Trials fully enrolled Diabetic Macular Edema (DME) BROADENING INDICATIONS Myopic CNV Trial fully enrolled in Asia Trial enrolling Branch Retinal Vein Occlusion (BRVO) Approved in U.S.; Filings globally Central Retinal Vein Occlusion (CRVO)
Slide 10: Securing the Future
10 SECURING THE FUTURE High affinity, fully-human antibody to PDGFR Goal to enter clinic with co-formulated product in 2H13 PDGFR High affinity, fully human antibody to ang2 Goal to enter into ophthalmology clinical development in 2013 ANG2 Novel formulation and delivery of EYLEA as well as evaluati
Slide 11: Opportunities in Cancer
11 OPPORTUNITIES IN CANCER Approved and launched in U.S. Discovered by Regeneron and co-developed with Sanofi Regeneron has worldwide co-commercialization rights Approved in the US Positive recommendation for approval by European CHMP EU approval expected 1Q13 Regeneron has worldwide co-commercializ
Slide 12: Expanding Late Stage Pipeline
12 EXPANDING LATE STAGE PIPELINE IL6R antibody for rheumatoid arthritis Sarilumab PCSK9 antibody for elevated cholesterol REGN727 IL4R antibody for Asthma and Atopic Dermatitis REGN668
Slide 13: PCSK9: Blocking PCSK9 Can Potentially Lower LDL-C Levels
13 (1) Tibolla G et al. Nutr Metab Cardiovasc Dis 2011;21:835-43. (2) Akram ON et al. Arterioscler Thromb Vasc Biol 2010;30:1279-81. (3) Duff CJ et al. Expert Opin Ther Targets 2011;15:157-68. (4) Horton JD et al. J Lipid Res 2009;50 Suppl:S172-7. (5) Cariou B et al. Atherosclerosis 2011;216:258-65.
Slide 14: REGN727: LDL Cholesterol Reduction
14 Phase 2 data published in The Lancet, Journal of the American College of Cardiology, and NEJM Significantly reduced mean LDL-C by 40% to 72% over 8 to 12 weeks in patients on stable dose of statins Most common adverse event was injection site reaction Mean percentage change in calculated LDL-C fr
Slide 15: REGN727: LDL Cholesterol Reduction Outcomes
15 FH I HIGH FH FH II OPTIONS I OPTIONS II MONO ALTERNATIVE LONG TERM COMBO I COMBO II N=105 18 months N=471 18 months N=250 18 months N=2,100 18 months N=306 12 months N=660 24 months N=250 6 months N=300 6 months N=100 6 months N=350 6 months N=18,000 (Event Driven) REGN727: LDL CHOLESTEROL REDUCT
Slide 16: Sarilumab: Rheumatoid Arthritis
16 SARILUMAB: RHEUMATOID ARTHRITIS Sarilumab is a fully human, high affinity, interleukin-6 receptor (IL-6R) antibody Positive Phase 2 study in rheumatoid arthritis Types and incidence of adverse events consistent with those previously reported with IL-6 inhibition Phase 3 MOBILITY trial fully enrol
Slide 17: REGN668: Asthma and Atopic Dermatitis
17 REGN668: ASTHMA AND ATOPIC DERMATITIS Positive proof of concept data for atopic dermatitis to be submitted for presentation at a medical conference in 2013 Positive proof of concept data for asthma to be submitted for presentation at a medical conference in 2013 Phase 2b initiation in both indica
Slide 18: Broad Antibody Pipeline
18 BROAD ANTIBODY PIPELINE Inflammation Therapeutic Focus Legend: Metabolism Oncology Ophthalmology Pain REGN421 (DII4 Antibody) Advanced malignancies REGN910 (ANG2 Antibody) Advanced malignancies REGN1033 (GDF8 Antibody) Metabolic disorders REGN1400 (ERBB3 Antibody) Advanced malignancies REGN846 (u
Slide 19: Sanofi Antibody Collaboration
19 SANOFI ANTIBODY COLLABORATION *100% development funding by Sanofi for all opted-in antibodies except 80% of an antibody’s Phase 3 costs incurred after receipt of the first positive results in a Phase 3 trial for that antibody. **Regeneron repays Sanofi for 50% of development costs out of profits.
Slide 20: Financials
20 FINANCIALS Year-end 2012 Year-end 2012 cash and cash and securities securities Year-end 2012 Year-end 2012 trade receivables receivables Non-GAAP Net Income * Unaudited Estimate $0 $50 $100 $150 $200 $250 1Q12 2Q12 3Q12
Slide 21: The Year Ahead
21 THE YEAR AHEAD • EYLEA US sales guidance of ~50% growth (i.e. $1.2B to $1.3B) • EYLEA ex-US launch in multiple additional countries COMMERCIAL MILESTONES • EYLEA approval in CRVO outside the U.S. • ZALTRAP approval in metastatic colorectal cancer outside the U.S. EXPECTED REGULATORY MILESTONES •
Regeneron Pharmaceuticals — J.P. Morgan Healthcare Conference 2013 on 6ix